Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 8/2008

01-06-2008 | Letter to the Editor

Leukocytapheresis for the treatment of refractory Henoch-Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy

Authors: Eishin Oki, Koji Tsugawa, Koichi Suzuki, Etsuro Ito, Hiroshi Tanaka

Published in: Rheumatology International | Issue 8/2008

Login to get access

Excerpt

Leukocytapheresis (LCAP) has been reported to be effective for the treatment of various autoimmune disorders [1‐3]. Recently, we encountered the dramatic efficacy of LCAP in a Japanese girl with refractory Henoch-Schönlein purpura (HSP) resistant to combined prednisolone (PDN) plus intravenous immunoglobulin (IVIG) administration. Although IVIG has been reported to be an effective treatment of choice for selected patients with refractory HSP [4], this was not the case in our patient. Thus, this case report may lend further support to the efficacy of LCAP for selected patients with refractory HSP. …
Literature
1.
Ueki Y, Yamasaki S, Kanamoto Y, Kawazu T, Yano M, Matsumoto K, Miyake S, Tominaga Y, Iwamoto U, Suemitsu J, Matsuno Y, Sizume Y, Takenaka Y, Eguchi K (2000) Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. Rheumatology (Oxford) 39:165–171CrossRef
2.
Sawada K, Ohnishi K, Fukui S,Yamada K, Yamamura M, Amano K, Wada M, Tanida N, Satomi M (1995) Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 30:322–329PubMedCrossRef
3.
Tanaka H, Tsugawa K, Nakahata T, Suzuki K, Ito E (2007) Leukocytapheresis for the treatment of refractory systemic-onset juvenile idiopathic arthritis. Clin Rheumatol 26:1014–1016PubMedCrossRef
4.
Fagbemi AAO, Torrente F, Hilson AJW, Thomson MA, Heuschkel RB, Murch SH (2007) Massive gastrointestinal haemorrhage in isolated intestinal Henoch-Schönlein purpura with response to intravenous immunoglobulin infusion. Eur J Pediatr 166:915–919PubMedCrossRef
5.
Kamitsuji H, Tani K, Yasui M, Taniguchi A, Taira K, Tsukada S, Iida Y, Kanki H, Fukui H (1987) Activity of blood coagulation factor XIII as prognostic indicator in patients with Henoch-Schönlein purpura: efficacy of factor XIII substitution. Eur J Pediatr 146:519–523PubMedCrossRef
6.
Nakahata T, Tanaka H, Suzuki K, Ito E (2003) Successful treatment with leukocytapheresis in refractory Henoch-Schönlein purpura. Clin Rheumatol 22:248–250PubMedCrossRef
Metadata
Title
Leukocytapheresis for the treatment of refractory Henoch-Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy
Authors
Eishin Oki
Koji Tsugawa
Koichi Suzuki
Etsuro Ito
Hiroshi Tanaka
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 8/2008
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0559-y

Other articles of this Issue 8/2008

Rheumatology International 8/2008 Go to the issue

Case Report

Application of three-dimensional computed tomography for the rheumatoid wrist

Original Article

sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis

Original Article

Sarcoidosis in patients with mixed connective tissue disease: clinical, genetic, serological and histological observations

Case Report

Superior vena cava syndrome associated with Behcet’s disease and 18 months’ follow up: a case report

Original Article

Celecoxib inhibits production of MMP and NO via down-regulation of NF-κB and JNK in a PGE2 independent manner in human articular chondrocytes

Erratum

TREX1 polymorphisms associated with autoantibodies in patients with systemic lupus erythematosus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits